Lymphocyte Biology Section and Center for Advanced Tissue Imaging, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD 20892, USA.
BostonGene, Waltham, MA 02453, USA.
Cancer Cell. 2024 Mar 11;42(3):444-463.e10. doi: 10.1016/j.ccell.2024.02.001. Epub 2024 Feb 29.
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Dynamic interactions between tumor B cells and the tumor microenvironment (TME) are hypothesized to contribute to the broad spectrum of clinical behaviors observed among FL patients. Despite the urgent need, existing clinical tools do not reliably predict disease behavior. Using a multi-modal strategy, we examined cell-intrinsic and -extrinsic factors governing progression and therapeutic outcomes in FL patients enrolled onto a prospective clinical trial. By leveraging the strengths of each platform, we identify several tumor-specific features and microenvironmental patterns enriched in individuals who experience early relapse, the most high-risk FL patients. These features include stromal desmoplasia and changes to the follicular growth pattern present 20 months before first progression and first relapse.
滤泡性淋巴瘤(FL)是一种通常无法治愈的恶性肿瘤,源于发育受阻的生发中心(GC)B 细胞。为了促进存活和免疫逃逸,肿瘤 B 细胞发生了显著的遗传改变,并广泛重塑了淋巴样微环境。肿瘤 B 细胞与肿瘤微环境(TME)之间的动态相互作用被假设有助于解释 FL 患者中观察到的广泛的临床行为。尽管存在迫切的需求,但现有的临床工具并不能可靠地预测疾病行为。我们使用多模态策略,研究了控制前瞻性临床试验中 FL 患者进展和治疗结果的细胞内和细胞外因素。通过利用每个平台的优势,我们确定了一些在早期复发的个体中富集的肿瘤特异性特征和微环境模式,早期复发的个体是 FL 患者中风险最高的人群。这些特征包括间质纤维化和滤泡生长模式的改变,它们在首次进展和首次复发前 20 个月就已经出现。